FrontPage is India's Stock Market Social Network
Join 50,000+ Traders and Investors
  1. Home
  2. CIPLA Forum

CIPLA

971.35 +3.25 (0.34%)
Updated 03:28 24/09 IST
92% Bullish
8% Bearish
25 Users have submitted 25 trade ideas of Rs. 1,099,368.44 for CIPLA
Disclaimer

Brokerage Reports

No. of reports in last year
9
No. of analysts
4
Average Consensus Forecast
882
Consensus Potential
-11.26%
See CIPLA Share Price Targets >>

CIPLA Share Price Discussion


Type
Buy
Instrument
CIPLA SEP21 FUT
Entry Price
₹980
Price@Trade
₹979.2
Target Price
₹1,000
Stop Price
₹970
Valid Till
Sep 30, 2021 3:20 AM
Margin
₹566,103.2 approx for 2600 Qty
Status
Waiting for entry
Like
Reply
swap_vert
Trade

Type
Buy
Instrument
CIPLA
Entry Price
₹975
Price@Trade
₹973
Target Price
₹1,000
Stop Price
₹967
Valid Till
Sep 24, 2021 3:20 AM
Margin
₹29,250 approx for 30 Qty
Status
Active
Like
Reply (1)
swap_vert
Trade
See all replies
TrackerBot @trackerbot
Sep 24 4:10 AM

Update
Trade Entered
Entry Price
₹975

Type
Buy
Instrument
CIPLA SEP21 980 CE
Entry Price
₹13
Price@Trade
₹13.35
Target Price
₹15
Stop Price
₹11
Valid Till
Sep 30, 2021 3:20 AM
Margin
₹8,450 approx for 650 Qty
Status
Target Achieved
Exit Price
₹15
Net P&L
+₹1,300 (+15.38%)
Like
Reply (2)
swap_vert
Trade
See all replies
TrackerBot @trackerbot
Sep 24 3:54 AM

Update
Trade Entered
Entry Price
₹13
TrackerBot @trackerbot
Sep 24 4:12 AM

Update
Target Achieved
Exit Price
₹15

Type
Sell
Instrument
CIPLA
Entry Price
₹972.8
Price@Trade
₹972.8
Target Price
₹960
Stop Price
₹976
Valid Till
Sep 24, 2021 3:20 AM
Margin
₹291,840 approx for 300 Qty
Status
Exited
Exit Price
₹973.45
Net P&L
-₹195 (-0.07%)
Like
Reply (1)
swap_vert
Trade
See all replies
Kiran Shigvan @kiranshigvan
Sep 24 4:03 AM

Update
Exited
Exit Price
₹973.45
Net P&L
-₹195 (-0.07%)

Type
Buy
Instrument
CIPLA SEP21 970 CE
Entry Price
₹17.15
Price@Trade
₹17.15
Target Price
₹100
Stop Price
₹10
Valid Till
Sep 30, 2021 3:20 AM
Margin
₹11,147.5 approx for 650 Qty
Status
Active
Like
Reply
swap_vert
Trade

Type
Buy
Instrument
CIPLA SEP21 990 CE
Entry Price
₹10.2
Price@Trade
₹10
Target Price
₹20
Stop Price
₹6.5
Valid Till
Sep 30, 2021 3:20 AM
Margin
₹6,630 approx for 650 Qty
Status
Active
Like
Reply (1)
swap_vert
Trade
See all replies
TrackerBot @trackerbot
Sep 24 4:10 AM

Update
Trade Entered
Entry Price
₹10.2

Type
Buy
Instrument
CIPLA SEP21 980 CE
Entry Price
₹14.8
Price@Trade
₹14.9
Target Price
₹30
Stop Price
₹14.1
Valid Till
Sep 24, 2021 3:20 AM
Margin
₹9,620 approx for 650 Qty
Status
Exited
Exit Price
₹14.55
Net P&L
-₹162.5 (-1.69%)
Like
Reply (2)
swap_vert
Trade
See all replies
TrackerBot @trackerbot
Sep 24 3:20 AM

Update
Trade Entered
Entry Price
₹14.8

Update
Exited
Exit Price
₹14.55
Net P&L
-₹162.5 (-1.69%)

Type
Buy
Instrument
CIPLA OCT21 1000 CE
Entry Price
₹49
Price@Trade
₹48.2
Target Price
₹55
Stop Price
₹30
Valid Till
Oct 28, 2021 3:20 AM
Margin
₹31,850 approx for 650 Qty
Status
Active
Like
Reply (1)
swap_vert
Trade
See all replies
TrackerBot @trackerbot
Sep 24 3:21 AM

Update
Trade Entered
Entry Price
₹49

Type
Buy
Instrument
CIPLA SEP21 970 CE
Entry Price
₹18.6
Price@Trade
₹18.6
Target Price
₹45
Stop Price
₹12
Valid Till
Sep 30, 2021 3:20 AM
Margin
₹12,090 approx for 650 Qty
Status
Active
Like
Reply
swap_vert
Trade

Type
Buy
Instrument
CIPLA
Entry Price
₹976
Price@Trade
₹976
Target Price
₹982
Stop Price
₹972
Valid Till
Sep 24, 2021 3:20 AM
Margin
₹244,000 approx for 250 Qty
Status
Exited
Exit Price
₹972.8
Net P&L
-₹800 (-0.33%)
Like
Reply (1)
swap_vert
Trade
See all replies
Ankit @ankit-H15LBbPJY
Sep 24 3:12 AM

Update
Exited
Exit Price
₹972.8
Net P&L
-₹800 (-0.33%)
C
Reputation: 5,408 • Sep 24 2:52 AM

Mcx Stocks & Index Advance INTRADAY calls :
Date: 24th sep 2021
Time follow after : 9:30 am"
Trend:
"EICHERMOT LEVELS - Buy at 2863.98 with Target of 2877.63/2890.35 , Add one lot 2860.05 ,Sell at 2856.12 with Target of 2836.47/2823.75"
"NIFTY21SEPFUT LEVELS - Buy at 17...
Read more...
Like
Reply

Type
Buy
Instrument
CIPLA
Entry Price
₹974.6
Price@Trade
₹974.6
Target Price
₹981
Stop Price
₹971
Valid Till
Sep 24, 2021 3:20 AM
Margin
₹97,460 approx for 100 Qty
Status
Exited
Exit Price
₹972.6
Net P&L
-₹200 (-0.21%)
Like
Reply (1)
swap_vert
Trade
See all replies
Ankit @ankit-H15LBbPJY
Sep 24 2:57 AM

Update
Exited
Exit Price
₹972.6
Net P&L
-₹200 (-0.21%)

Type
Buy
Instrument
CIPLA
Entry Price
₹970
Price@Trade
₹971.9
Target Price
₹1,060
Stop Price
₹950
Valid Till
Sep 23, 2022 3:20 AM
Margin
₹97,000 approx for 100 Qty
Status
Exited
Exit Price
₹973.15
Net P&L
+₹315 (+0.32%)
Like
Reply (2)
swap_vert
Trade
See all replies
TrackerBot @trackerbot
Sep 24 2:46 AM

Update
Trade Entered
Entry Price
₹970
Amogh Kadam @amoghkadam
Sep 24 3:32 AM

Update
Exited
Exit Price
₹973.15
Net P&L
+₹315 (+0.32%)

Type
Buy
Instrument
CIPLA OCT21 980 CE
Entry Price
₹37
Price@Trade
₹40.05
Target Price
₹100
Stop Price
₹0
Valid Till
Oct 28, 2021 3:20 AM
Margin
₹24,050 approx for 650 Qty
Status
Exited before entry
Like
Reply (1)
swap_vert
Trade
See all replies

Update
Exited before entry
Price @ Update
₹57.05

Type
Buy
Instrument
CIPLA OCT21 980 CE
Entry Price
₹40.25
Price@Trade
₹40.8
Target Price
₹100
Stop Price
₹0
Valid Till
Oct 28, 2021 3:20 AM
Margin
₹26,162.5 approx for 650 Qty
Status
Active
Like
Reply (1)
swap_vert
Trade
See all replies
TrackerBot @trackerbot
Sep 23 8:33 AM

Update
Trade Entered
Entry Price
₹40.25

Type
Buy
Instrument
CIPLA OCT21 980 CE
Entry Price
₹40.2
Price@Trade
₹40.2
Target Price
₹45
Stop Price
₹30
Valid Till
Oct 22, 2021 3:20 AM
Margin
₹26,130 approx for 650 Qty
Status
Target Achieved
Exit Price
₹45.25
Net P&L
+₹3,282.5 (+12.56%)
Like
Reply (1)
swap_vert
Trade
See all replies
TrackerBot @trackerbot
Sep 24 2:46 AM

Update
Target Achieved
Exit Price
₹45.25

Type
Buy
Instrument
CIPLA OCT21 980 CE
Entry Price
₹36
Price@Trade
₹39.3
Target Price
₹70
Stop Price
₹20
Valid Till
Oct 28, 2021 3:20 AM
Margin
₹46,800 approx for 1300 Qty
Status
Exited before entry
Like
Reply (1)
swap_vert
Trade
See all replies
parveen @parveen-ByJ94H4PD
Sep 24 2:56 AM

Update
Exited before entry
Price @ Update
₹54.85

Type
Buy
Instrument
CIPLA SEP21 960 CE
Entry Price
₹20
Price@Trade
₹20.1
Target Price
₹36.3
Stop Price
₹9  ₹20.7
Valid Till
Sep 30, 2021 3:20 AM
Margin
₹130,000 approx for 6500 Qty
Status
Stoploss Hit
Exit Price
20.7
Net P&L
+₹4,550 (+3.5%)
Like
Reply (3)
swap_vert
Trade
See all replies
TrackerBot @trackerbot
Sep 23 8:08 AM

Update
Trade Entered
Entry Price
₹20
vipul khuman @vipulkhuman
Sep 23 8:23 AM

Update
Stoploss Trailed
Price @ Update
₹21
Original SL
₹9
New SL
20.7
TrackerBot @trackerbot
Sep 23 8:29 AM

Update
Stoploss Hit
Exit Price
20.7

Type
Buy
Instrument
CIPLA OCT21 1000 CE
Entry Price
₹28.8
Price@Trade
₹28.8
Target Price
₹35
Stop Price
₹25
Valid Till
Oct 28, 2021 3:20 AM
Margin
₹18,720 approx for 650 Qty
Status
Target Achieved
Exit Price
₹47.45
Net P&L
+₹12,122.5 (+64.76%)
Like
Reply (1)
swap_vert
Trade
See all replies
TrackerBot @trackerbot
Sep 24 2:46 AM

Update
Target Achieved
Exit Price
₹47.45

Type
Buy
Instrument
CIPLA SEP21 1000 CE
Entry Price
₹5.35
Price@Trade
₹5.35
Target Price
₹8
Stop Price
₹5
Valid Till
Sep 30, 2021 3:20 AM
Margin
₹3,477.5 approx for 650 Qty
Status
Target Achieved
Exit Price
₹8
Net P&L
+₹1,722.5 (+49.53%)
Like
Reply (1)
swap_vert
Trade
See all replies
TrackerBot @trackerbot
Sep 24 3:05 AM

Update
Target Achieved
Exit Price
₹8

CIPLA Ratings

Long term CIPLA rating by FrontPage users
3.6/5 (5 Ratings)
Find answers to all your questions on live CIPLA message board: Is CIPLA buy or sell? Should I buy CIPLA shares? Why are CIPLA shares falling? Should I invest in CIPLA stock?

Join FrontPage
Hero Img
FrontPage is India's favorite stock discussions community
Join 2,00,000 Indian traders and discuss trades, strategies, news & views on any stock.
  • CIPLA - Share Price - Fundamentals

    keyboard_arrow_down
    Market Capitalization42,645.7
    Enterprise Value42,471.14
    Price to Earnings29.77
    Price to Book Value2.7
    Return on Capital Employed0.13
    Return on Equity0.1
    Face Value2
    Dividend Yield0.01
  • CIPLA - Brokerage Reports

    keyboard_arrow_down
    DateBrokerageCallTarget
    15-May-21Dolat CapitalAccumulate940
    1-Feb-21Prabhudas LilladherAccumulate913
    1-Feb-21HDFC SecuritiesBuy1,020
    14-Dec-20Prabhudas LilladherBuy887
    14-Dec-20HDFC SecuritiesBuy940
    CIPLA Brokerage Price Target
  • CIPLA Share Price - Historical (₹)

    keyboard_arrow_down
    DateOpenHighLowClose
    Sep 24969.6983.4960.45967.65
    Sep 23965.45970959.5968.1
    Sep 22952.25974.25951.65963.5
    Sep 21935959933956.1
    Sep 20953953929.8938.1
  • CIPLA Share Price - Daily Moving Averages (DMA)

    keyboard_arrow_down
    20 Day Moving Average₹949.27
    30 Day Moving Average₹933.92
    50 Day Moving Average₹934.32
    100 Day Moving Average₹938.06
    200 Day Moving Average₹882.65
  • CIPLA - Profit And Loss

    keyboard_arrow_down
    CONSOLIDATEDMar-18Mar-17 % Change
    Revenue11,39010,974.580.04
    Operating Profit2,1181,596.260.33
    Profit Before Tax1,9111,186.940.61
    Net Income1,469974.940.51
  • CIPLA - Balance Sheet

    keyboard_arrow_down
    CONSOLIDATEDMar-19Mar-18 % Change
    Shareholder's Funds15,78214,1140.12
    Total Liabilities2,6373,497-0.25
    Total Assets18,41917,6100.05
  • CIPLA - Cash Flow

    keyboard_arrow_down
    CONSOLIDATEDMar-18Mar-17 % Change
    Cash from Operating Activity1,1172,205.56-0.49
    Cash from Investing Activity-593-1,191.75-0.5
    Cash from Financing Activity-351-1,008.97-0.65
    Net Cash Flow1734.8434.74
  • CIPLA - Ratios

    keyboard_arrow_down
    CONSOLIDATEDMar-18Mar-17
    Return on Assets0.080.06
    Return on Equity0.10.08
    Return on Capital Employed0.130.09
  • CIPLA - 3 year Growth

    keyboard_arrow_down
    3 Year CAGR Growth in Revenue0.12
    3 Year CAGR Growth in Operating Profit0.08
    3 Year CAGR Growth in EBIDTA0.16
    3 Year CAGR Growth in Net Income0.24
    3 Yr CAGR Growth - Diluted EPS0.24
  • CIPLA - 5 year Growth

    keyboard_arrow_down
    5 Year CAGR Growth in Revenue0.39
    5 Year CAGR Growth in Operating ProfitNA
    5 Year CAGR Growth in EBIDTA0.05
    5 Year CAGR Growth in Net Income-0.03
    3 Yr CAGR Growth - Diluted EPS-0.03
  • CIPLA - Recent News

    keyboard_arrow_down
    NewsBot
    Sep 7 4:46 AM
    Buy Cipla, target price Rs 1140: Emkay Global
    The Economic Times
    NewsBot
    Sep 2 6:51 AM
    Cipla partners with IIT Delhi backed startup Clensta for distribution of waterless technology products
    The Economic Times
    NewsBot
    Aug 25 9:26 AM
    Cipla, Kemwell Biopharma join hands to develop biosimilars
    The Economic Times
    NewsBot
    Aug 23 8:11 AM
    For US-facing pharma cos, Q2 & Q3 likely to be soft quarters: Nithya Balasubramanian
    The Economic Times
    NewsBot
    Aug 12 6:51 AM
    Cipla gets USFDA nod for generic product
    The Economic Times
    NewsBot
    Aug 9 8:11 AM
    Cipla confident about earning trajectory over next couple of quarters: Umang Vohra
    The Economic Times
    NewsBot
    Aug 8 2:41 AM
    Rotation from midcaps to largecaps bodes well for market: Siddhartha Khemka
    The Economic Times
    NewsBot
    Aug 8 1:51 AM
    Nothing commercial yet on Moderna’s vaccine in India: Kedar Upadhye, CEO Cipla
    The Economic Times
    NewsBot
    Aug 6 4:06 AM
    Buy Cipla, target price Rs 1140: Emkay Global
    The Economic Times
    NewsBot
    Aug 6 3:01 AM
    Sensex gains in early trade, Nifty tops 16,300; Voda Idea surges 10%
    The Economic Times
  • CIPLA - Related Communities

    keyboard_arrow_down
    Sun Pharmaceutical Industries Ltd. NS...
    Aurobindo Pharma Ltd. NSE: AUROPHARMA...
    Biocon Ltd. NSE: BIOCON | BSE: 532523...
    Lupin Ltd. NSE: LUPIN | BSE: 500257 |...
    Dr. Reddy's Laboratories Ltd. NSE: DR...
    Glenmark Pharmaceuticals Ltd. NSE: GL...
    Divi's Laboratories Ltd. NSE: DIVISLA...
    Cadila Healthcare Ltd. NSE: CADILAHC ...
    Piramal Enterprises Ltd. NSE: PEL | B...
    Apollo Hospitals Enterprise Ltd. NSE:...
  • CIPLA - More Information

    keyboard_arrow_down

    Cipla Ltd:
    Cipla Limited, along with its multiple subsidiaries, is responsible for the manufacture and sale of pharmaceutical goods in India. It provides a variety of formulations and active pharmaceutical ingredients in various aspects like urology, ophthalmology, malaria, oncology, neurosciences, women’s and children’s health, hepatitis, critical care, osteoporosis, and infectious diseases.
    The company provides multiple inhalation therapy devices like nasal sprays, metered-dose inhalers, accessory devices, dry powder inhalers, and nebulizers. Apart from manufacturing and selling these products in India, it also exports to Russia, the Middle East, Asia, Australia, New Zealand, and Latin America and other regions internationally.
    On 17th of August in 1935, Cipla got registered as a public limited with a capital of Rs. 6 lakh and is a Mumbai based Company in India. During the Second World War, when the drug supplies were topped in 1941, the company started to produce fine chemicals. At this point, Cipla dedicated its facilities to provide a variety of ingenious drugs.
    About Company Information:
    Within the next two decades after the inception of the Second World War, in 1960, the company started its operations in Vikhroli, Mumbai. This was their second plant. At this unit, they produced fine chemicals related to natural products. Ampicillin was manufactured for the first time in the country in 1968 by Cipla. To cultivate medicinal plants, the company then started their Agricultural Research Division, located in Bangalore, in the year 1972.
    In 1982, the company started operating in its fourth manufacturing unit located in Patalganga, Maharashtra. The company collaborated with the National Chemical Laboratory in Pune, in the year 1984 to produce anti-cancer drugs like vincristine and vinblastine. Collaborating with Indian Institute of Chemical Technology, in 1991, a drug considered to be a breakthrough in chemotherapy, named etoposide was launched by the company. Later on, an antiretroviral drug called zidovudine was also manufactured by the company in association with Indian Institute of Chemical Technology.
    Nevirapine, an antiretroviral drug used to stop AIDS transmission in a child from a mother, was launched by the company in 1999. Cipla was the first company, outside of Europe and U.S.A, which began CFC-free-inhalers, in the year 2000. In February in 2007, the company allied with the Drugs for Neglected Diseases Initiative for developing a new anti-malarial drug. This was a worldwide initiative taken by the company with a non-profit organization like DNDI.
    In April of 2010, the company started its operations for commercial production of a variety of pharmaceutical formulations at their SEZ project in Indore, MP. On the 21st of July, 2012, Cipla revealed that they were to collaborate with DNDi (a non-profit R&D organization) for developing an improved form of antiretroviral (ARV) combo therapy which will specifically treat kids affected by HIV/AIDS.
    On the 17th of April, 2013, Cipla announced that they would be the first to launch a biosimilar of Etanercept in the country which will be targeted to treat rheumatic disorders. On the 20th of February in 2014, Cipla announced their alliance with MSD which would give them a non-exclusive license using which they would sell raltegravir 400mg tablet (a drug from MSD) along with marketing and distribution of the drug but down under a different brand name.
    In February 2015, Cipla revealed to have been awarded a Global Fund ARV Tender which is worth USD 188.95 million for developing antiretroviral drugs.
    On the 12th of October, 2016, Cipla announced the formal closing of US FDA inspection that was conducted in July-August in the year 2015. Cipla was given the establishment inspection report by the FDA, and it was held AT THE Indore Unit of the company. On the 30th of November, 2017, Cipla publicized the fact that the company had received approval from the World Health Organization (WHO) for a product name Q-TIB, which is essentially a combination of novel fixed-dose within a single tablet form. This was the first combination to ever exist in the world.
    How Cipla Ltd, is categorised as a Pharmaceutical and Healthcare Sector, and Pharmaceutical Industry :
    The Pharmaceutical Industry includes companies that derive their business by researching, discovering, developing, manufacturing, and marketing and distributing pharmaceutical medicines and drugs.
    Cipla Ltd is categorized under the Health care sector and Hospitals and Medical services Industry. Healthcare sectors consist of firms involved in the medical space. It is one of the multiple sectors that comprise a range of businesses, including ones that offer medical services directly, or to those that work to develop, create and market medical equipment and medicines. It also includes the other services that provide medical insurance and other related products, and many more.
    The stocks of health care companies mostly have mixed performance. It is due to the inherent challenges to the industry each year, regulatory uncertainties, fiscal policy concerns, and more.
    Cipla Ltd, Competitors and Sector Peers:
    Abbott India Ltd. ABBIND
    Alembic Ltd. ALELTD
    Alembic Pharmaceuticals Ltd. ALEPHA
    Alkem Laboratories Ltd. ALKLAB
    Alpa Laboratories Ltd. ALPLAB
    Ambalal Sarabhai Enterprises Ltd. AMBSAR
    AstraZeneca Pharma India Ltd. ASTZEN
    Bafna Pharmaceuticals Ltd. BAFPHA
    Bajaj Healthcare Ltd. BAJHEA
    Biocon Ltd. BIOLTD
    Cian Healthcare Ltd.
    Cipla Ltd. CIPLTD
    Concord Drugs Ltd. CONDRU
    Dishman Pharmaceuticals & Chemicals Ltd.[Merged] DISPHA
    Divi's Laboratories Ltd. DIVIL
    Dr. Reddy's Laboratories Ltd. DR
    GlaxoSmithKline Pharmaceuticals Ltd. GLAPHA
    Glenmark Pharmaceuticals Ltd. GLEPHL
    IOL Chemicals and Pharmaceuticals Ltd. IOLCHE
    Lincoln Pharmaceuticals Ltd. LINPHA
    Lupin Ltd. LUPLTD
    Madhuveer Com 18 Network Ltd. TOHPHA
    Mahavir Advanced Remedies Ltd. INDAME
    Makers Laboratories Ltd. MAKLAB
    Natco Pharma Ltd. NATPHA
    Natural Capsules Ltd. NATCAP
    Ranbaxy Laboratories Ltd. RANLAB
    Sanofi India Ltd. AVEPHA
    Sharon Bio-Medicine Ltd. SHAPHA
    Sun Pharmaceutical Industries Ltd. SUN28
    Zenith Healthcare Ltd. ZENHEA
    Zyden Gentec Ltd. ZYDGEN
SOURCE: Data from D'Market via Quandl. Intraday data delayed 15 minutes.
DISCLAIMER: Information is provided "as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and FrontPage will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein.